nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—CYP1A2—Clobetasol propionate—psoriasis	0.133	0.24	CbGbCtD
Maprotiline—CYP1A2—Methoxsalen—psoriasis	0.0696	0.126	CbGbCtD
Maprotiline—CYP2D6—Hydroxyurea—psoriasis	0.0627	0.113	CbGbCtD
Maprotiline—CYP2D6—Cholecalciferol—psoriasis	0.038	0.0687	CbGbCtD
Maprotiline—ABCB1—Mycophenolate mofetil—psoriasis	0.035	0.0632	CbGbCtD
Maprotiline—ABCB1—Betamethasone—psoriasis	0.03	0.0543	CbGbCtD
Maprotiline—ABCB1—Prednisolone—psoriasis	0.0296	0.0535	CbGbCtD
Maprotiline—ABCB1—Hydrocortisone—psoriasis	0.0281	0.0508	CbGbCtD
Maprotiline—ABCB1—Prednisone—psoriasis	0.028	0.0506	CbGbCtD
Maprotiline—ABCB1—Cyclosporine—psoriasis	0.0265	0.0479	CbGbCtD
Maprotiline—CYP2D6—Cyclosporine—psoriasis	0.025	0.0452	CbGbCtD
Maprotiline—ABCB1—Dexamethasone—psoriasis	0.0175	0.0316	CbGbCtD
Maprotiline—CYP2D6—Dexamethasone—psoriasis	0.0164	0.0297	CbGbCtD
Maprotiline—ABCB1—Methotrexate—psoriasis	0.014	0.0254	CbGbCtD
Maprotiline—Nervous system disorder—Hydrocortisone—psoriasis	0.000274	0.000645	CcSEcCtD
Maprotiline—Eye disorder—Prednisone—psoriasis	0.000274	0.000643	CcSEcCtD
Maprotiline—Tachycardia—Hydrocortisone—psoriasis	0.000273	0.000641	CcSEcCtD
Maprotiline—Somnolence—Mycophenolate mofetil—psoriasis	0.000273	0.000641	CcSEcCtD
Maprotiline—Drowsiness—Methotrexate—psoriasis	0.000273	0.000641	CcSEcCtD
Maprotiline—Infestation—Methotrexate—psoriasis	0.000273	0.000641	CcSEcCtD
Maprotiline—Infestation NOS—Methotrexate—psoriasis	0.000273	0.000641	CcSEcCtD
Maprotiline—Flushing—Prednisone—psoriasis	0.000272	0.000639	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000272	0.000639	CcSEcCtD
Maprotiline—Skin disorder—Hydrocortisone—psoriasis	0.000272	0.000638	CcSEcCtD
Maprotiline—Fatigue—Cyclosporine—psoriasis	0.000271	0.000638	CcSEcCtD
Maprotiline—Hyperhidrosis—Hydrocortisone—psoriasis	0.00027	0.000635	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.00027	0.000635	CcSEcCtD
Maprotiline—Dyspepsia—Mycophenolate mofetil—psoriasis	0.00027	0.000635	CcSEcCtD
Maprotiline—Constipation—Cyclosporine—psoriasis	0.000269	0.000632	CcSEcCtD
Maprotiline—Dry mouth—Triamcinolone—psoriasis	0.000269	0.000631	CcSEcCtD
Maprotiline—Diarrhoea—Mycophenolic acid—psoriasis	0.000266	0.000626	CcSEcCtD
Maprotiline—Stomatitis—Methotrexate—psoriasis	0.000266	0.000625	CcSEcCtD
Maprotiline—Angiopathy—Prednisone—psoriasis	0.000266	0.000625	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000265	0.000623	CcSEcCtD
Maprotiline—Oedema—Triamcinolone—psoriasis	0.000263	0.000619	CcSEcCtD
Maprotiline—Syncope—Dexamethasone—psoriasis	0.000263	0.000617	CcSEcCtD
Maprotiline—Syncope—Betamethasone—psoriasis	0.000263	0.000617	CcSEcCtD
Maprotiline—Constipation—Mycophenolate mofetil—psoriasis	0.000263	0.000617	CcSEcCtD
Maprotiline—Arrhythmia—Prednisone—psoriasis	0.000262	0.000615	CcSEcCtD
Maprotiline—Infection—Triamcinolone—psoriasis	0.000262	0.000615	CcSEcCtD
Maprotiline—Hypotension—Hydrocortisone—psoriasis	0.000261	0.000614	CcSEcCtD
Maprotiline—Feeling abnormal—Cyclosporine—psoriasis	0.000259	0.000609	CcSEcCtD
Maprotiline—Shock—Triamcinolone—psoriasis	0.000259	0.000609	CcSEcCtD
Maprotiline—Insomnia—Prednisolone—psoriasis	0.000259	0.000609	CcSEcCtD
Maprotiline—Alopecia—Prednisone—psoriasis	0.000259	0.000608	CcSEcCtD
Maprotiline—Hepatobiliary disease—Methotrexate—psoriasis	0.000258	0.000606	CcSEcCtD
Maprotiline—Gastrointestinal pain—Cyclosporine—psoriasis	0.000257	0.000605	CcSEcCtD
Maprotiline—Loss of consciousness—Dexamethasone—psoriasis	0.000257	0.000605	CcSEcCtD
Maprotiline—Loss of consciousness—Betamethasone—psoriasis	0.000257	0.000605	CcSEcCtD
Maprotiline—Dizziness—Mycophenolic acid—psoriasis	0.000257	0.000605	CcSEcCtD
Maprotiline—Paraesthesia—Prednisolone—psoriasis	0.000257	0.000604	CcSEcCtD
Maprotiline—Tachycardia—Triamcinolone—psoriasis	0.000257	0.000604	CcSEcCtD
Maprotiline—Malnutrition—Prednisone—psoriasis	0.000255	0.000599	CcSEcCtD
Maprotiline—Hyperhidrosis—Triamcinolone—psoriasis	0.000255	0.000598	CcSEcCtD
Maprotiline—Agranulocytosis—Methotrexate—psoriasis	0.000255	0.000598	CcSEcCtD
Maprotiline—Convulsion—Dexamethasone—psoriasis	0.000254	0.000596	CcSEcCtD
Maprotiline—Convulsion—Betamethasone—psoriasis	0.000254	0.000596	CcSEcCtD
Maprotiline—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000253	0.000595	CcSEcCtD
Maprotiline—Insomnia—Hydrocortisone—psoriasis	0.000253	0.000594	CcSEcCtD
Maprotiline—Hypertension—Dexamethasone—psoriasis	0.000253	0.000594	CcSEcCtD
Maprotiline—Hypertension—Betamethasone—psoriasis	0.000253	0.000594	CcSEcCtD
Maprotiline—Paraesthesia—Hydrocortisone—psoriasis	0.000251	0.00059	CcSEcCtD
Maprotiline—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000251	0.00059	CcSEcCtD
Maprotiline—Urticaria—Cyclosporine—psoriasis	0.00025	0.000588	CcSEcCtD
Maprotiline—Abdominal pain—Cyclosporine—psoriasis	0.000249	0.000585	CcSEcCtD
Maprotiline—Body temperature increased—Cyclosporine—psoriasis	0.000249	0.000585	CcSEcCtD
Maprotiline—Anxiety—Betamethasone—psoriasis	0.000249	0.000584	CcSEcCtD
Maprotiline—Anxiety—Dexamethasone—psoriasis	0.000249	0.000584	CcSEcCtD
Maprotiline—Vomiting—Mycophenolic acid—psoriasis	0.000247	0.000581	CcSEcCtD
Maprotiline—Dyspepsia—Hydrocortisone—psoriasis	0.000246	0.000579	CcSEcCtD
Maprotiline—Rash—Mycophenolic acid—psoriasis	0.000245	0.000576	CcSEcCtD
Maprotiline—Dermatitis—Mycophenolic acid—psoriasis	0.000245	0.000576	CcSEcCtD
Maprotiline—Hepatitis—Methotrexate—psoriasis	0.000245	0.000575	CcSEcCtD
Maprotiline—Urticaria—Mycophenolate mofetil—psoriasis	0.000244	0.000573	CcSEcCtD
Maprotiline—Headache—Mycophenolic acid—psoriasis	0.000244	0.000573	CcSEcCtD
Maprotiline—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000243	0.00057	CcSEcCtD
Maprotiline—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000243	0.00057	CcSEcCtD
Maprotiline—Urinary tract disorder—Methotrexate—psoriasis	0.000242	0.000568	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000242	0.000567	CcSEcCtD
Maprotiline—Fatigue—Hydrocortisone—psoriasis	0.000241	0.000567	CcSEcCtD
Maprotiline—Vision blurred—Prednisone—psoriasis	0.00024	0.000565	CcSEcCtD
Maprotiline—Urethral disorder—Methotrexate—psoriasis	0.00024	0.000564	CcSEcCtD
Maprotiline—Oedema—Dexamethasone—psoriasis	0.000239	0.000562	CcSEcCtD
Maprotiline—Oedema—Betamethasone—psoriasis	0.000239	0.000562	CcSEcCtD
Maprotiline—Insomnia—Triamcinolone—psoriasis	0.000238	0.00056	CcSEcCtD
Maprotiline—Infection—Dexamethasone—psoriasis	0.000237	0.000558	CcSEcCtD
Maprotiline—Infection—Betamethasone—psoriasis	0.000237	0.000558	CcSEcCtD
Maprotiline—Paraesthesia—Triamcinolone—psoriasis	0.000237	0.000556	CcSEcCtD
Maprotiline—Feeling abnormal—Prednisolone—psoriasis	0.000236	0.000555	CcSEcCtD
Maprotiline—Shock—Dexamethasone—psoriasis	0.000235	0.000552	CcSEcCtD
Maprotiline—Shock—Betamethasone—psoriasis	0.000235	0.000552	CcSEcCtD
Maprotiline—Nervous system disorder—Betamethasone—psoriasis	0.000234	0.000551	CcSEcCtD
Maprotiline—Nervous system disorder—Dexamethasone—psoriasis	0.000234	0.000551	CcSEcCtD
Maprotiline—Agitation—Prednisone—psoriasis	0.000234	0.000551	CcSEcCtD
Maprotiline—Thrombocytopenia—Dexamethasone—psoriasis	0.000234	0.00055	CcSEcCtD
Maprotiline—Thrombocytopenia—Betamethasone—psoriasis	0.000234	0.00055	CcSEcCtD
Maprotiline—Tachycardia—Betamethasone—psoriasis	0.000233	0.000548	CcSEcCtD
Maprotiline—Tachycardia—Dexamethasone—psoriasis	0.000233	0.000548	CcSEcCtD
Maprotiline—Dyspepsia—Triamcinolone—psoriasis	0.000232	0.000545	CcSEcCtD
Maprotiline—Erythema multiforme—Methotrexate—psoriasis	0.000232	0.000544	CcSEcCtD
Maprotiline—Nausea—Mycophenolic acid—psoriasis	0.000231	0.000543	CcSEcCtD
Maprotiline—Hyperhidrosis—Betamethasone—psoriasis	0.000231	0.000543	CcSEcCtD
Maprotiline—Hyperhidrosis—Dexamethasone—psoriasis	0.000231	0.000543	CcSEcCtD
Maprotiline—Feeling abnormal—Hydrocortisone—psoriasis	0.000231	0.000542	CcSEcCtD
Maprotiline—Eye disorder—Methotrexate—psoriasis	0.000229	0.000538	CcSEcCtD
Maprotiline—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000229	0.000537	CcSEcCtD
Maprotiline—Syncope—Prednisone—psoriasis	0.000229	0.000537	CcSEcCtD
Maprotiline—Tinnitus—Methotrexate—psoriasis	0.000228	0.000536	CcSEcCtD
Maprotiline—Urticaria—Prednisolone—psoriasis	0.000228	0.000535	CcSEcCtD
Maprotiline—Cardiac disorder—Methotrexate—psoriasis	0.000227	0.000534	CcSEcCtD
Maprotiline—Fatigue—Triamcinolone—psoriasis	0.000227	0.000534	CcSEcCtD
Maprotiline—Asthenia—Cyclosporine—psoriasis	0.000226	0.000531	CcSEcCtD
Maprotiline—Loss of consciousness—Prednisone—psoriasis	0.000224	0.000527	CcSEcCtD
Maprotiline—Hypotension—Dexamethasone—psoriasis	0.000223	0.000525	CcSEcCtD
Maprotiline—Hypotension—Betamethasone—psoriasis	0.000223	0.000525	CcSEcCtD
Maprotiline—Pruritus—Cyclosporine—psoriasis	0.000223	0.000523	CcSEcCtD
Maprotiline—Urticaria—Hydrocortisone—psoriasis	0.000222	0.000522	CcSEcCtD
Maprotiline—Angiopathy—Methotrexate—psoriasis	0.000222	0.000522	CcSEcCtD
Maprotiline—Abdominal pain—Hydrocortisone—psoriasis	0.000221	0.00052	CcSEcCtD
Maprotiline—Body temperature increased—Hydrocortisone—psoriasis	0.000221	0.00052	CcSEcCtD
Maprotiline—Convulsion—Prednisone—psoriasis	0.000221	0.000519	CcSEcCtD
Maprotiline—Mediastinal disorder—Methotrexate—psoriasis	0.000221	0.000518	CcSEcCtD
Maprotiline—Asthenia—Mycophenolate mofetil—psoriasis	0.00022	0.000518	CcSEcCtD
Maprotiline—Hypertension—Prednisone—psoriasis	0.00022	0.000517	CcSEcCtD
Maprotiline—Pruritus—Mycophenolate mofetil—psoriasis	0.000217	0.00051	CcSEcCtD
Maprotiline—Feeling abnormal—Triamcinolone—psoriasis	0.000217	0.00051	CcSEcCtD
Maprotiline—Anxiety—Prednisone—psoriasis	0.000216	0.000508	CcSEcCtD
Maprotiline—Alopecia—Methotrexate—psoriasis	0.000216	0.000508	CcSEcCtD
Maprotiline—Insomnia—Betamethasone—psoriasis	0.000216	0.000508	CcSEcCtD
Maprotiline—Insomnia—Dexamethasone—psoriasis	0.000216	0.000508	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000216	0.000507	CcSEcCtD
Maprotiline—Diarrhoea—Cyclosporine—psoriasis	0.000215	0.000506	CcSEcCtD
Maprotiline—Paraesthesia—Betamethasone—psoriasis	0.000215	0.000504	CcSEcCtD
Maprotiline—Paraesthesia—Dexamethasone—psoriasis	0.000215	0.000504	CcSEcCtD
Maprotiline—Malnutrition—Methotrexate—psoriasis	0.000213	0.000501	CcSEcCtD
Maprotiline—Dyspepsia—Dexamethasone—psoriasis	0.00021	0.000494	CcSEcCtD
Maprotiline—Dyspepsia—Betamethasone—psoriasis	0.00021	0.000494	CcSEcCtD
Maprotiline—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00021	0.000494	CcSEcCtD
Maprotiline—Urticaria—Triamcinolone—psoriasis	0.000209	0.000492	CcSEcCtD
Maprotiline—Dysgeusia—Methotrexate—psoriasis	0.000209	0.00049	CcSEcCtD
Maprotiline—Body temperature increased—Triamcinolone—psoriasis	0.000208	0.000489	CcSEcCtD
Maprotiline—Dizziness—Cyclosporine—psoriasis	0.000208	0.000489	CcSEcCtD
Maprotiline—Oedema—Prednisone—psoriasis	0.000208	0.000489	CcSEcCtD
Maprotiline—Infection—Prednisone—psoriasis	0.000207	0.000486	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000206	0.000485	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Betamethasone—psoriasis	0.000206	0.000485	CcSEcCtD
Maprotiline—Fatigue—Dexamethasone—psoriasis	0.000206	0.000484	CcSEcCtD
Maprotiline—Fatigue—Betamethasone—psoriasis	0.000206	0.000484	CcSEcCtD
Maprotiline—Shock—Prednisone—psoriasis	0.000205	0.000481	CcSEcCtD
Maprotiline—Nervous system disorder—Prednisone—psoriasis	0.000204	0.00048	CcSEcCtD
Maprotiline—Tachycardia—Prednisone—psoriasis	0.000203	0.000477	CcSEcCtD
Maprotiline—Dizziness—Mycophenolate mofetil—psoriasis	0.000203	0.000477	CcSEcCtD
Maprotiline—Skin disorder—Prednisone—psoriasis	0.000202	0.000475	CcSEcCtD
Maprotiline—Hyperhidrosis—Prednisone—psoriasis	0.000201	0.000473	CcSEcCtD
Maprotiline—Vision blurred—Methotrexate—psoriasis	0.000201	0.000472	CcSEcCtD
Maprotiline—Asthenia—Hydrocortisone—psoriasis	0.000201	0.000472	CcSEcCtD
Maprotiline—Vomiting—Cyclosporine—psoriasis	0.0002	0.00047	CcSEcCtD
Maprotiline—Rash—Cyclosporine—psoriasis	0.000199	0.000466	CcSEcCtD
Maprotiline—Dermatitis—Cyclosporine—psoriasis	0.000198	0.000466	CcSEcCtD
Maprotiline—Pruritus—Hydrocortisone—psoriasis	0.000198	0.000465	CcSEcCtD
Maprotiline—Headache—Cyclosporine—psoriasis	0.000197	0.000463	CcSEcCtD
Maprotiline—Feeling abnormal—Dexamethasone—psoriasis	0.000197	0.000463	CcSEcCtD
Maprotiline—Feeling abnormal—Betamethasone—psoriasis	0.000197	0.000463	CcSEcCtD
Maprotiline—Gastrointestinal pain—Betamethasone—psoriasis	0.000195	0.000459	CcSEcCtD
Maprotiline—Gastrointestinal pain—Dexamethasone—psoriasis	0.000195	0.000459	CcSEcCtD
Maprotiline—Vomiting—Mycophenolate mofetil—psoriasis	0.000195	0.000459	CcSEcCtD
Maprotiline—Rash—Mycophenolate mofetil—psoriasis	0.000194	0.000455	CcSEcCtD
Maprotiline—Dermatitis—Mycophenolate mofetil—psoriasis	0.000193	0.000454	CcSEcCtD
Maprotiline—Headache—Mycophenolate mofetil—psoriasis	0.000192	0.000452	CcSEcCtD
Maprotiline—Diarrhoea—Hydrocortisone—psoriasis	0.000191	0.00045	CcSEcCtD
Maprotiline—Leukopenia—Methotrexate—psoriasis	0.000191	0.000448	CcSEcCtD
Maprotiline—Urticaria—Betamethasone—psoriasis	0.00019	0.000446	CcSEcCtD
Maprotiline—Urticaria—Dexamethasone—psoriasis	0.00019	0.000446	CcSEcCtD
Maprotiline—Dizziness—Prednisolone—psoriasis	0.000189	0.000445	CcSEcCtD
Maprotiline—Asthenia—Triamcinolone—psoriasis	0.000189	0.000444	CcSEcCtD
Maprotiline—Abdominal pain—Betamethasone—psoriasis	0.000189	0.000444	CcSEcCtD
Maprotiline—Body temperature increased—Betamethasone—psoriasis	0.000189	0.000444	CcSEcCtD
Maprotiline—Body temperature increased—Dexamethasone—psoriasis	0.000189	0.000444	CcSEcCtD
Maprotiline—Abdominal pain—Dexamethasone—psoriasis	0.000189	0.000444	CcSEcCtD
Maprotiline—Insomnia—Prednisone—psoriasis	0.000188	0.000442	CcSEcCtD
Maprotiline—Nausea—Cyclosporine—psoriasis	0.000187	0.000439	CcSEcCtD
Maprotiline—Paraesthesia—Prednisone—psoriasis	0.000187	0.000439	CcSEcCtD
Maprotiline—Pruritus—Triamcinolone—psoriasis	0.000186	0.000438	CcSEcCtD
Maprotiline—Dizziness—Hydrocortisone—psoriasis	0.000185	0.000435	CcSEcCtD
Maprotiline—Convulsion—Methotrexate—psoriasis	0.000185	0.000434	CcSEcCtD
Maprotiline—Dyspepsia—Prednisone—psoriasis	0.000183	0.00043	CcSEcCtD
Maprotiline—Nausea—Mycophenolate mofetil—psoriasis	0.000182	0.000429	CcSEcCtD
Maprotiline—Rash—Prednisolone—psoriasis	0.000181	0.000424	CcSEcCtD
Maprotiline—Dermatitis—Prednisolone—psoriasis	0.00018	0.000424	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00018	0.000423	CcSEcCtD
Maprotiline—Fatigue—Prednisone—psoriasis	0.000179	0.000422	CcSEcCtD
Maprotiline—Headache—Prednisolone—psoriasis	0.000179	0.000422	CcSEcCtD
Maprotiline—Constipation—Prednisone—psoriasis	0.000178	0.000418	CcSEcCtD
Maprotiline—Vomiting—Hydrocortisone—psoriasis	0.000178	0.000418	CcSEcCtD
Maprotiline—Rash—Hydrocortisone—psoriasis	0.000176	0.000414	CcSEcCtD
Maprotiline—Dermatitis—Hydrocortisone—psoriasis	0.000176	0.000414	CcSEcCtD
Maprotiline—Confusional state—Methotrexate—psoriasis	0.000175	0.000412	CcSEcCtD
Maprotiline—Headache—Hydrocortisone—psoriasis	0.000175	0.000412	CcSEcCtD
Maprotiline—Dizziness—Triamcinolone—psoriasis	0.000174	0.000409	CcSEcCtD
Maprotiline—Infection—Methotrexate—psoriasis	0.000173	0.000406	CcSEcCtD
Maprotiline—Feeling abnormal—Prednisone—psoriasis	0.000172	0.000403	CcSEcCtD
Maprotiline—Asthenia—Dexamethasone—psoriasis	0.000172	0.000403	CcSEcCtD
Maprotiline—Asthenia—Betamethasone—psoriasis	0.000172	0.000403	CcSEcCtD
Maprotiline—Nervous system disorder—Methotrexate—psoriasis	0.000171	0.000401	CcSEcCtD
Maprotiline—Thrombocytopenia—Methotrexate—psoriasis	0.00017	0.0004	CcSEcCtD
Maprotiline—Gastrointestinal pain—Prednisone—psoriasis	0.00017	0.0004	CcSEcCtD
Maprotiline—Nausea—Prednisolone—psoriasis	0.00017	0.0004	CcSEcCtD
Maprotiline—Pruritus—Dexamethasone—psoriasis	0.000169	0.000397	CcSEcCtD
Maprotiline—Pruritus—Betamethasone—psoriasis	0.000169	0.000397	CcSEcCtD
Maprotiline—Skin disorder—Methotrexate—psoriasis	0.000169	0.000397	CcSEcCtD
Maprotiline—Hyperhidrosis—Methotrexate—psoriasis	0.000168	0.000395	CcSEcCtD
Maprotiline—Vomiting—Triamcinolone—psoriasis	0.000168	0.000394	CcSEcCtD
Maprotiline—Nausea—Hydrocortisone—psoriasis	0.000166	0.00039	CcSEcCtD
Maprotiline—Rash—Triamcinolone—psoriasis	0.000166	0.00039	CcSEcCtD
Maprotiline—Dermatitis—Triamcinolone—psoriasis	0.000166	0.00039	CcSEcCtD
Maprotiline—Urticaria—Prednisone—psoriasis	0.000165	0.000389	CcSEcCtD
Maprotiline—Headache—Triamcinolone—psoriasis	0.000165	0.000388	CcSEcCtD
Maprotiline—Abdominal pain—Prednisone—psoriasis	0.000165	0.000387	CcSEcCtD
Maprotiline—Body temperature increased—Prednisone—psoriasis	0.000165	0.000387	CcSEcCtD
Maprotiline—Diarrhoea—Betamethasone—psoriasis	0.000164	0.000384	CcSEcCtD
Maprotiline—Diarrhoea—Dexamethasone—psoriasis	0.000164	0.000384	CcSEcCtD
Maprotiline—Hypotension—Methotrexate—psoriasis	0.000163	0.000382	CcSEcCtD
Maprotiline—Dizziness—Betamethasone—psoriasis	0.000158	0.000371	CcSEcCtD
Maprotiline—Dizziness—Dexamethasone—psoriasis	0.000158	0.000371	CcSEcCtD
Maprotiline—Insomnia—Methotrexate—psoriasis	0.000157	0.00037	CcSEcCtD
Maprotiline—Nausea—Triamcinolone—psoriasis	0.000156	0.000368	CcSEcCtD
Maprotiline—Paraesthesia—Methotrexate—psoriasis	0.000156	0.000367	CcSEcCtD
Maprotiline—Somnolence—Methotrexate—psoriasis	0.000155	0.000363	CcSEcCtD
Maprotiline—Dyspepsia—Methotrexate—psoriasis	0.000153	0.00036	CcSEcCtD
Maprotiline—Vomiting—Dexamethasone—psoriasis	0.000152	0.000357	CcSEcCtD
Maprotiline—Vomiting—Betamethasone—psoriasis	0.000152	0.000357	CcSEcCtD
Maprotiline—Rash—Dexamethasone—psoriasis	0.000151	0.000354	CcSEcCtD
Maprotiline—Rash—Betamethasone—psoriasis	0.000151	0.000354	CcSEcCtD
Maprotiline—Dermatitis—Dexamethasone—psoriasis	0.000151	0.000354	CcSEcCtD
Maprotiline—Dermatitis—Betamethasone—psoriasis	0.000151	0.000354	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Methotrexate—psoriasis	0.00015	0.000353	CcSEcCtD
Maprotiline—Fatigue—Methotrexate—psoriasis	0.00015	0.000352	CcSEcCtD
Maprotiline—Headache—Betamethasone—psoriasis	0.00015	0.000352	CcSEcCtD
Maprotiline—Headache—Dexamethasone—psoriasis	0.00015	0.000352	CcSEcCtD
Maprotiline—Asthenia—Prednisone—psoriasis	0.000149	0.000351	CcSEcCtD
Maprotiline—Pruritus—Prednisone—psoriasis	0.000147	0.000346	CcSEcCtD
Maprotiline—Feeling abnormal—Methotrexate—psoriasis	0.000143	0.000337	CcSEcCtD
Maprotiline—Diarrhoea—Prednisone—psoriasis	0.000142	0.000335	CcSEcCtD
Maprotiline—Gastrointestinal pain—Methotrexate—psoriasis	0.000142	0.000334	CcSEcCtD
Maprotiline—Nausea—Dexamethasone—psoriasis	0.000142	0.000334	CcSEcCtD
Maprotiline—Nausea—Betamethasone—psoriasis	0.000142	0.000334	CcSEcCtD
Maprotiline—Urticaria—Methotrexate—psoriasis	0.000138	0.000325	CcSEcCtD
Maprotiline—Dizziness—Prednisone—psoriasis	0.000138	0.000323	CcSEcCtD
Maprotiline—Body temperature increased—Methotrexate—psoriasis	0.000138	0.000323	CcSEcCtD
Maprotiline—Abdominal pain—Methotrexate—psoriasis	0.000138	0.000323	CcSEcCtD
Maprotiline—Vomiting—Prednisone—psoriasis	0.000132	0.000311	CcSEcCtD
Maprotiline—Rash—Prednisone—psoriasis	0.000131	0.000308	CcSEcCtD
Maprotiline—Dermatitis—Prednisone—psoriasis	0.000131	0.000308	CcSEcCtD
Maprotiline—Headache—Prednisone—psoriasis	0.00013	0.000306	CcSEcCtD
Maprotiline—Asthenia—Methotrexate—psoriasis	0.000125	0.000293	CcSEcCtD
Maprotiline—Nausea—Prednisone—psoriasis	0.000124	0.00029	CcSEcCtD
Maprotiline—Pruritus—Methotrexate—psoriasis	0.000123	0.000289	CcSEcCtD
Maprotiline—Diarrhoea—Methotrexate—psoriasis	0.000119	0.00028	CcSEcCtD
Maprotiline—Dizziness—Methotrexate—psoriasis	0.000115	0.00027	CcSEcCtD
Maprotiline—Vomiting—Methotrexate—psoriasis	0.000111	0.00026	CcSEcCtD
Maprotiline—Rash—Methotrexate—psoriasis	0.00011	0.000258	CcSEcCtD
Maprotiline—Dermatitis—Methotrexate—psoriasis	0.00011	0.000257	CcSEcCtD
Maprotiline—Headache—Methotrexate—psoriasis	0.000109	0.000256	CcSEcCtD
Maprotiline—Nausea—Methotrexate—psoriasis	0.000103	0.000243	CcSEcCtD
Maprotiline—HTR2A—Signaling Pathways—TAGAP—psoriasis	2.4e-05	0.00113	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TAGAP—psoriasis	2.4e-05	0.00113	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—CCL20—psoriasis	2.39e-05	0.00113	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TAGAP—psoriasis	2.39e-05	0.00113	CbGpPWpGaD
Maprotiline—HTR2A—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.39e-05	0.00113	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TAGAP—psoriasis	2.38e-05	0.00112	CbGpPWpGaD
Maprotiline—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.38e-05	0.00112	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TAGAP—psoriasis	2.36e-05	0.00111	CbGpPWpGaD
Maprotiline—CHRM2—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.34e-05	0.0011	CbGpPWpGaD
Maprotiline—HTR7—Circadian rythm related genes—TP53—psoriasis	2.3e-05	0.00108	CbGpPWpGaD
Maprotiline—DRD2—Circadian rythm related genes—JUN—psoriasis	2.27e-05	0.00107	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—CCL20—psoriasis	2.25e-05	0.00106	CbGpPWpGaD
Maprotiline—CHRM1—Circadian rythm related genes—JUN—psoriasis	2.22e-05	0.00105	CbGpPWpGaD
Maprotiline—ABCB1—Allograft Rejection—TNF—psoriasis	2.22e-05	0.00105	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—NDUFA5—psoriasis	2.22e-05	0.00105	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.21e-05	0.00104	CbGpPWpGaD
Maprotiline—DRD2—G alpha (i) signalling events—CXCL8—psoriasis	2.15e-05	0.00101	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CCL20—psoriasis	2.12e-05	0.001	CbGpPWpGaD
Maprotiline—HTR7—Circadian rythm related genes—IL6—psoriasis	2.11e-05	0.000993	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—NDUFA5—psoriasis	2.09e-05	0.000985	CbGpPWpGaD
Maprotiline—CHRM2—G alpha (i) signalling events—CXCL8—psoriasis	2.08e-05	0.00098	CbGpPWpGaD
Maprotiline—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.06e-05	0.000972	CbGpPWpGaD
Maprotiline—HTR2A—SIDS Susceptibility Pathways—TNF—psoriasis	2.05e-05	0.000964	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CCL20—psoriasis	2.03e-05	0.000959	CbGpPWpGaD
Maprotiline—CHRM2—SIDS Susceptibility Pathways—TNF—psoriasis	2.01e-05	0.000947	CbGpPWpGaD
Maprotiline—HTR7—GPCR ligand binding—CXCL8—psoriasis	2e-05	0.000944	CbGpPWpGaD
Maprotiline—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.97e-05	0.000927	CbGpPWpGaD
Maprotiline—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.94e-05	0.000914	CbGpPWpGaD
Maprotiline—CHRM4—GPCR ligand binding—CXCL8—psoriasis	1.89e-05	0.000892	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CYP2S1—psoriasis	1.89e-05	0.000889	CbGpPWpGaD
Maprotiline—CHRM5—GPCR ligand binding—CXCL8—psoriasis	1.81e-05	0.000854	CbGpPWpGaD
Maprotiline—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.8e-05	0.000851	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CYP2S1—psoriasis	1.78e-05	0.000838	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—NDUFA5—psoriasis	1.77e-05	0.000835	CbGpPWpGaD
Maprotiline—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.71e-05	0.000807	CbGpPWpGaD
Maprotiline—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.68e-05	0.000794	CbGpPWpGaD
Maprotiline—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.68e-05	0.000792	CbGpPWpGaD
Maprotiline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.67e-05	0.00079	CbGpPWpGaD
Maprotiline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.67e-05	0.000787	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CCL20—psoriasis	1.66e-05	0.000781	CbGpPWpGaD
Maprotiline—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.65e-05	0.000779	CbGpPWpGaD
Maprotiline—HTR2A—SIDS Susceptibility Pathways—IL6—psoriasis	1.65e-05	0.000778	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.65e-05	0.000778	CbGpPWpGaD
Maprotiline—CHRM2—SIDS Susceptibility Pathways—IL6—psoriasis	1.62e-05	0.000764	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CYP2S1—psoriasis	1.51e-05	0.00071	CbGpPWpGaD
Maprotiline—DRD2—Circadian rythm related genes—TP53—psoriasis	1.5e-05	0.000706	CbGpPWpGaD
Maprotiline—HTR2C—GPCR ligand binding—CXCL8—psoriasis	1.48e-05	0.000696	CbGpPWpGaD
Maprotiline—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.47e-05	0.000693	CbGpPWpGaD
Maprotiline—CHRM1—Circadian rythm related genes—TP53—psoriasis	1.46e-05	0.000691	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCL20—psoriasis	1.46e-05	0.00069	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.46e-05	0.000689	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—CARM1—psoriasis	1.45e-05	0.000684	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCL20—psoriasis	1.44e-05	0.000679	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCL20—psoriasis	1.44e-05	0.000677	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCL20—psoriasis	1.43e-05	0.000675	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCL20—psoriasis	1.43e-05	0.000673	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCL20—psoriasis	1.41e-05	0.000666	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.41e-05	0.000663	CbGpPWpGaD
Maprotiline—DRD2—Circadian rythm related genes—IL6—psoriasis	1.37e-05	0.000646	CbGpPWpGaD
Maprotiline—CHRM1—Circadian rythm related genes—IL6—psoriasis	1.34e-05	0.000632	CbGpPWpGaD
Maprotiline—DRD2—GPCR ligand binding—CXCL8—psoriasis	1.3e-05	0.000614	CbGpPWpGaD
Maprotiline—HTR2A—GPCR ligand binding—CXCL8—psoriasis	1.28e-05	0.000604	CbGpPWpGaD
Maprotiline—HRH1—GPCR ligand binding—CXCL8—psoriasis	1.28e-05	0.000603	CbGpPWpGaD
Maprotiline—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.28e-05	0.000602	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.28e-05	0.000602	CbGpPWpGaD
Maprotiline—CHRM1—GPCR ligand binding—CXCL8—psoriasis	1.28e-05	0.000601	CbGpPWpGaD
Maprotiline—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.27e-05	0.000601	CbGpPWpGaD
Maprotiline—CHRM3—GPCR ligand binding—CXCL8—psoriasis	1.27e-05	0.000599	CbGpPWpGaD
Maprotiline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.27e-05	0.000599	CbGpPWpGaD
Maprotiline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.27e-05	0.000597	CbGpPWpGaD
Maprotiline—CHRM2—GPCR ligand binding—CXCL8—psoriasis	1.26e-05	0.000593	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—SOCS1—psoriasis	1.24e-05	0.000584	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—TYK2—psoriasis	1.18e-05	0.000557	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—SOCS1—psoriasis	1.17e-05	0.000551	CbGpPWpGaD
Maprotiline—HTR7—GPCR downstream signaling—CXCL8—psoriasis	1.13e-05	0.000534	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—SOCS1—psoriasis	1.12e-05	0.000528	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—TYK2—psoriasis	1.11e-05	0.000526	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.09e-05	0.000516	CbGpPWpGaD
Maprotiline—CHRM4—GPCR downstream signaling—CXCL8—psoriasis	1.07e-05	0.000504	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—TYK2—psoriasis	1.07e-05	0.000503	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—CXCL8—psoriasis	1.03e-05	0.000485	CbGpPWpGaD
Maprotiline—CHRM5—GPCR downstream signaling—CXCL8—psoriasis	1.02e-05	0.000483	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—CXCL8—psoriasis	9.71e-06	0.000458	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	9.65e-06	0.000455	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—CXCL8—psoriasis	9.3e-06	0.000438	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CARM1—psoriasis	9.21e-06	0.000434	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—APOE—psoriasis	9.14e-06	0.000431	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—LEP—psoriasis	9.14e-06	0.000431	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SOCS1—psoriasis	9.13e-06	0.00043	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—CAT—psoriasis	8.93e-06	0.000421	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—TYK2—psoriasis	8.7e-06	0.00041	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CARM1—psoriasis	8.68e-06	0.000409	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—LEP—psoriasis	8.63e-06	0.000407	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—APOE—psoriasis	8.63e-06	0.000407	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—NFKBIA—psoriasis	8.51e-06	0.000401	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	8.35e-06	0.000393	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—LEP—psoriasis	8.26e-06	0.00039	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—APOE—psoriasis	8.26e-06	0.00039	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SOCS1—psoriasis	8.06e-06	0.00038	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—NFKBIA—psoriasis	8.04e-06	0.000379	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SOCS1—psoriasis	7.93e-06	0.000374	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SOCS1—psoriasis	7.91e-06	0.000373	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.89e-06	0.000372	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SOCS1—psoriasis	7.88e-06	0.000372	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SOCS1—psoriasis	7.86e-06	0.00037	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SOCS1—psoriasis	7.78e-06	0.000367	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—NFKBIA—psoriasis	7.7e-06	0.000363	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—TYK2—psoriasis	7.68e-06	0.000362	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—CXCL8—psoriasis	7.58e-06	0.000357	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—TYK2—psoriasis	7.56e-06	0.000356	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—TYK2—psoriasis	7.54e-06	0.000356	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—TYK2—psoriasis	7.52e-06	0.000354	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—TYK2—psoriasis	7.49e-06	0.000353	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—TYK2—psoriasis	7.42e-06	0.00035	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—CXCL8—psoriasis	7.36e-06	0.000347	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CARM1—psoriasis	7.35e-06	0.000347	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	7.25e-06	0.000342	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—CXCL8—psoriasis	7.23e-06	0.000341	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—CXCL8—psoriasis	7.21e-06	0.00034	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—CXCL8—psoriasis	7.18e-06	0.000339	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—CXCL8—psoriasis	7.12e-06	0.000335	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TYK2—psoriasis	6.97e-06	0.000329	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—APOE—psoriasis	6.94e-06	0.000327	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.87e-06	0.000324	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—LEP—psoriasis	6.74e-06	0.000318	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—APOE—psoriasis	6.74e-06	0.000318	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—CXCL8—psoriasis	6.69e-06	0.000315	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TYK2—psoriasis	6.59e-06	0.00031	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—CXCL8—psoriasis	6.58e-06	0.00031	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—CXCL8—psoriasis	6.57e-06	0.00031	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—CXCL8—psoriasis	6.55e-06	0.000309	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—CXCL8—psoriasis	6.52e-06	0.000308	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—CXCL8—psoriasis	6.46e-06	0.000305	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TYK2—psoriasis	6.31e-06	0.000297	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NFKBIA—psoriasis	6.28e-06	0.000296	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—CXCL8—psoriasis	6.07e-06	0.000286	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PPARG—psoriasis	6.04e-06	0.000285	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—LEP—psoriasis	5.95e-06	0.00028	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—APOE—psoriasis	5.95e-06	0.00028	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—APOE—psoriasis	5.85e-06	0.000276	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—LEP—psoriasis	5.85e-06	0.000276	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—LEP—psoriasis	5.84e-06	0.000275	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—APOE—psoriasis	5.84e-06	0.000275	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—LEP—psoriasis	5.82e-06	0.000274	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—APOE—psoriasis	5.82e-06	0.000274	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—APOE—psoriasis	5.8e-06	0.000273	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—LEP—psoriasis	5.8e-06	0.000273	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—IL6—psoriasis	5.77e-06	0.000272	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—LEP—psoriasis	5.74e-06	0.000271	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—APOE—psoriasis	5.74e-06	0.000271	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CXCL8—psoriasis	5.73e-06	0.00027	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CAT—psoriasis	5.66e-06	0.000267	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—JUN—psoriasis	5.65e-06	0.000266	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NFKBIA—psoriasis	5.54e-06	0.000261	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CXCL8—psoriasis	5.49e-06	0.000259	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—IL6—psoriasis	5.45e-06	0.000257	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NFKBIA—psoriasis	5.45e-06	0.000257	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NFKBIA—psoriasis	5.44e-06	0.000256	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—NFKB1—psoriasis	5.43e-06	0.000256	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NFKBIA—psoriasis	5.42e-06	0.000256	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NFKBIA—psoriasis	5.4e-06	0.000255	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NFKBIA—psoriasis	5.35e-06	0.000252	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CAT—psoriasis	5.34e-06	0.000252	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—JUN—psoriasis	5.33e-06	0.000251	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—IL6—psoriasis	5.22e-06	0.000246	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TYK2—psoriasis	5.14e-06	0.000242	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—NFKB1—psoriasis	5.13e-06	0.000242	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—JUN—psoriasis	5.11e-06	0.000241	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—VEGFA—psoriasis	4.93e-06	0.000232	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—NFKB1—psoriasis	4.91e-06	0.000232	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—STAT3—psoriasis	4.88e-06	0.00023	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—VEGFA—psoriasis	4.66e-06	0.00022	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—STAT3—psoriasis	4.61e-06	0.000217	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TYK2—psoriasis	4.54e-06	0.000214	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CAT—psoriasis	4.52e-06	0.000213	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CXCL8—psoriasis	4.48e-06	0.000211	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TYK2—psoriasis	4.46e-06	0.00021	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—VEGFA—psoriasis	4.46e-06	0.00021	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TYK2—psoriasis	4.46e-06	0.00021	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TYK2—psoriasis	4.44e-06	0.000209	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TYK2—psoriasis	4.43e-06	0.000209	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—STAT3—psoriasis	4.42e-06	0.000208	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—APOE—psoriasis	4.4e-06	0.000207	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TYK2—psoriasis	4.38e-06	0.000207	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—IL6—psoriasis	4.26e-06	0.000201	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—JUN—psoriasis	4.16e-06	0.000196	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—APOE—psoriasis	4.15e-06	0.000196	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NFKB1—psoriasis	4.01e-06	0.000189	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CXCL8—psoriasis	3.95e-06	0.000186	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CXCL8—psoriasis	3.89e-06	0.000183	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CXCL8—psoriasis	3.88e-06	0.000183	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CXCL8—psoriasis	3.87e-06	0.000182	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CXCL8—psoriasis	3.85e-06	0.000182	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PPARG—psoriasis	3.83e-06	0.000181	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CXCL8—psoriasis	3.82e-06	0.00018	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—IL6—psoriasis	3.76e-06	0.000177	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—psoriasis	3.73e-06	0.000176	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—IL6—psoriasis	3.7e-06	0.000174	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—IL6—psoriasis	3.69e-06	0.000174	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—IL6—psoriasis	3.68e-06	0.000173	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—JUN—psoriasis	3.67e-06	0.000173	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—IL6—psoriasis	3.67e-06	0.000173	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—VEGFA—psoriasis	3.64e-06	0.000171	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—IL6—psoriasis	3.63e-06	0.000171	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—JUN—psoriasis	3.61e-06	0.00017	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPARG—psoriasis	3.61e-06	0.00017	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—JUN—psoriasis	3.61e-06	0.00017	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—STAT3—psoriasis	3.6e-06	0.00017	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—JUN—psoriasis	3.59e-06	0.000169	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—JUN—psoriasis	3.58e-06	0.000169	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—JUN—psoriasis	3.55e-06	0.000167	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NFKB1—psoriasis	3.54e-06	0.000167	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—psoriasis	3.52e-06	0.000166	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—APOE—psoriasis	3.51e-06	0.000166	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NFKB1—psoriasis	3.48e-06	0.000164	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NFKB1—psoriasis	3.47e-06	0.000164	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NFKB1—psoriasis	3.46e-06	0.000163	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NFKB1—psoriasis	3.45e-06	0.000163	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NFKB1—psoriasis	3.42e-06	0.000161	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—IL6—psoriasis	3.41e-06	0.000161	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—psoriasis	3.37e-06	0.000159	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL6—psoriasis	3.22e-06	0.000152	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—VEGFA—psoriasis	3.21e-06	0.000151	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—STAT3—psoriasis	3.18e-06	0.00015	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—VEGFA—psoriasis	3.16e-06	0.000149	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—VEGFA—psoriasis	3.15e-06	0.000149	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—VEGFA—psoriasis	3.14e-06	0.000148	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—VEGFA—psoriasis	3.13e-06	0.000148	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—STAT3—psoriasis	3.13e-06	0.000147	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—STAT3—psoriasis	3.12e-06	0.000147	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—STAT3—psoriasis	3.11e-06	0.000147	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—VEGFA—psoriasis	3.1e-06	0.000146	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—STAT3—psoriasis	3.1e-06	0.000146	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—IL6—psoriasis	3.08e-06	0.000145	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—STAT3—psoriasis	3.07e-06	0.000145	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARG—psoriasis	3.06e-06	0.000144	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—psoriasis	2.75e-06	0.00013	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL6—psoriasis	2.51e-06	0.000119	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—psoriasis	2.42e-06	0.000114	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—psoriasis	2.39e-06	0.000112	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—psoriasis	2.38e-06	0.000112	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—psoriasis	2.37e-06	0.000112	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—psoriasis	2.37e-06	0.000111	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—psoriasis	2.34e-06	0.00011	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL6—psoriasis	2.22e-06	0.000105	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL6—psoriasis	2.18e-06	0.000103	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL6—psoriasis	2.18e-06	0.000103	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL6—psoriasis	2.17e-06	0.000102	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL6—psoriasis	2.17e-06	0.000102	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL6—psoriasis	2.14e-06	0.000101	CbGpPWpGaD
